Alzheimer’s Research Study
Beth Israel Deaconess Hospital-Plymouth Participating in Largest Brain Amyloid Scan Research Study for the Detection of Alzheimer’s disease
Beth Israel Deaconess Hospital-Plymouth is now part of the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study. Patients, ages 65 and older, with cognitive impairment of uncertain cause can receive a Medicare-covered amyloid positron emission tomography (PET) scan by participating in the IDEAS Study.
The Study will follow more than 18,000 Medicare beneficiaries to determine the clinical value of a brain PET scan to detect the hallmark brain amyloid accumulation of Alzheimer’s disease in diagnosing and managing treatment of patients. Information from this scan can help exclude underlying Alzheimer’s disease and may help guide patient management. The goal is to show that, by enabling an early and accurate diagnosis of Alzheimer’s, this novel technology can improve health outcomes, such as reducing unnecessary hospitalizations and emergency room visits, and increasing appropriate prescription of medications.
Locally, neurologist Dr. Donald Marks is currently referring patients to the study at BIDPlymouth. “There are a number of criteria for who gets the scan and all patients referred for the IDEAS-Study must be seen for a formal neurology consult prior to being referred to the study.”
Patients cannot directly enroll in the IDEAS Study. IDEAS Study dementia specialists, like Dr. Marks, must enroll patients whose cases meet the study criteria and refer them to registered PET imaging facilities, such as BID-Plymouth, for an amyloid PET scan. These scans will be performed and interpreted by radiologists, Dr. Stephen Trehu, Dr. Joshua Stuhlfaut, and Dr. Parag Shah, who are registered to take part in the IDEAS Study.
For further information on the study visit ideas-study.org and for questions regarding eligibility and enrollment, please contact Dr. Marks at 508-746-5060.